IBN (InvestorBrandNetwork), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Stock2Me Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.
The Stock2Me Podcast features a fascinating array of companies and individuals, many of whom are actively revolutionizing age-old business practices within their respective markets. Stock2Me’s latest podcast features two-time Olympic gold medalist Abby Wambach speaking on behalf of Odyssey Health Inc. (OTC: ODYY), a medical technology company developing a drug/device combination intended to treat concussion. Wambach is a member of Odyssey’s sports advisory board, which aims to support the company’s efforts to enhance public awareness of traumatic brain injuries and concussions, as well as the need for an FDA-approved therapy.
Throughout the interview, Wambach discussed her soccer career and how concerns about brain health led her to team with Odyssey Health.
“I had a unique, long career playing for the Women’s National Team. I played in many Olympics and World Cups, won a bunch of golds and, in my retirement (I’ve been retired for six years), I’ve had a lot of time to reflect on the time that I played,” Wambach said. “I played soccer for 30 years, and one of the biggest concerns that I have going into the rest of my life is my brain health and wellness. Of course, a lot of us only think of concussions and CTE as it relates to NFL football, but the reality is that brain trauma happens in every sport.”
“There’s just so little research done not only on concussions themselves but also when you break it down into the genders… So many less dollars get siphoned over to the women’s side, not only because it’s newer in terms of the history of sport, but because women historically haven’t been given the same amount of research dollars to figure out what’s going on with their bodies and why,” she continued. “That’s why I partnered with Jake [Vanlandingham] and the Odyssey crew, because it’s so important not only to the rest of my life, but to make sure that our kids are playing sports in the most safe and healthy way. It’s really important to talk about this and be in the proactive lane to be able to somehow solve this issue of head trauma and concussions in sport.”
Wambach then highlighted the factors guiding her decision to work with Odyssey Health to raise awareness of the pressing need for an FDA-approved therapy for concussion.
“The first and foremost thing that we need to figure out is how to treat and prevent concussions from the get-go. A really important way to figure out how to do that is research – getting the science and the data as much as we possibly can so that we can affect some of those preventative measures and the treatment measures,” Wambach added. “We have to have an actionable avenue in how we utilize the research. We can get all the data that we want… But, at the end of the day… how do we make sure that we can take care of our community – not just sports, but also the military and the elderly. Any person who is dealing with any kind of head trauma will greatly benefit from research and the production of treatments like the medicine that Odyssey is behind.”
Join IBN’s Stuart Smith and National Soccer Hall of Famer Abby Wambach of the Odyssey Health Inc. (OTC: ODYY) sports advisory board to learn more about the outsized risk of head trauma among female athletes and the seasoned management team guiding the ongoing development of Odyssey’s clinical pipeline.
To hear the whole podcast and subscribe for future episodes, visit https://podcast.stock2me.com.
The latest installment of The Stock2Me Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers and the growing IBN Podcast Series. For more than 15 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.
To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine
About Odyssey Health Inc.
Odyssey Health Inc. (OTC: ODYY) is a medical company with a focus in the area of life-saving medical solutions. Odyssey’s corporate mission is to create, acquire and develop distinct assets, intellectual property, and exceptional technologies that provide meaningful medical solutions. The company is focused on areas that have an identified technological advantage, provide superior clinical utility, and have a substantial market opportunity. For more information, visit the company’s website at www.OdysseyHealthInc.com
IBN consists of financial brands introduced to the investment public over the course of 15+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.
Through NetworkNewsWire (“NNW”) and its Investor Brand Platform, IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.
For more information, please visit https://www.InvestorBrandNetwork.com
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.